| Title | High prevalence and mortality of Pneumocystis jirovecii pneumonia in anti-MDA5 antibody-positive dermatomyositis |
| Authors | Chen, Xixia Shu, Xiaoming He, Linrong Yang, Hanbo Lu, Xin Wang, Guochun Ge, Yongpeng |
| Affiliation | Peking Univ China, Japan Friendship Sch Clin Med, Beijing, Peoples R China China Japan Friendship Hosp, Dept Rheumatol, Key Myositis Labs, Beijing, Peoples R China China Japan Friendship Hosp, Dept Rheumatol, Yinghua East Rd, Beijing 100029, Peoples R China |
| Keywords | CARINII-PNEUMONIA CLASSIFICATION DISEASES POLYMYOSITIS RITUXIMAB |
| Issue Date | Feb-2023 |
| Publisher | RHEUMATOLOGY |
| Abstract | Objectives To identify potential risk factors and prognostic factors of Pneumocystis jirovecii pneumonia (PJP) infection in anti-melanoma differentiation-associated gene 5 antibody-positive DM (anti-MDA5+ DM) patients, and to evaluate the diagnostic performance of metagenomic next-generation sequencing (mNGS). Methods Anti-MDA5+ DM patients who underwent mNGS or real-time PCR for PJP detection were recruited. The potential risk factors for PJP occurrence and death were analysed via Logistic regression and Cox proportional hazards regression, respectively. The diagnostic efficacy of mNGS was compared with the conventional methods. Results 91 patients were enrolled and 44 were assigned to PJP+ group. The PJP detection rate was 48.4%. PJP often occurred in the first 3 months (68.2%) of the disease; this period also showed the highest mortality rate (20.5%). Fever and increased lactate dehydrogenase (LDH) were independent risk factors for PJP occurrence, while trimethoprim-sulfamethoxazole (TMP/SMZ) prophylaxis was an independent protective factor (all P < 0.05). Older age and increased LDH were predictors for mortality in patients with anti-MDA5+ DM and PJP (all P < 0.05). In addition, we found that mNGS had a sensitivity of 100.0% and specificity of 90.0% in diagnosing PJP, with the highest area under the curve of 0.95 (P < 0.001). Conclusion PJP has high prevalence and mortality in anti-MDA5+ DM. It is crucial for clinicians to identify high-risk patients and promptly institute TMP/SMZ to prevent PJP. mNGS is the preferred approach for pathogen detection in anti-MDA5+ DM when PJP is suspected. |
| URI | http://hdl.handle.net/20.500.11897/672114 |
| ISSN | 1462-0324 |
| DOI | 10.1093/rheumatology/kead063 |
| Indexed | SCI(E) |
| Appears in Collections: | 待认领 |
